Antibody method for treatment of a disease in which the target cells are cells which express CD20
US9873745B2 · kind B2 · utility
4Cited by
0References
17Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Aug 17, 2015 |
| Grant date | Jan 23, 2018 |
| Priority date | — |
| Expiry date | Aug 17, 2035 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2510/02
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to a monoclonal antibody method directed against CD20 antigen including administration of an anti CD20 antibody wherein each of the light chains thereof has the murine-human chimeric amino acid sequence SEQ ID NO: 28, and each of the heavy chains thereof has the murine-human chimeric amino acid sequence SEQ ID NO: 20.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.